Unlock instant, AI-driven research and patent intelligence for your innovation.

Application of Antiplatelet Thrombolysin in Preparation of Drugs for Treating Anemia

An anti-platelet and thrombolytic technology, applied in the field of medicine, can solve the problem of meaningless etiological treatment, achieve the effect of reducing aggregation and prolonging survival time

Active Publication Date: 2021-10-15
ZHAOKE PHARMA HEFEI
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

There is no definite change in the genetic composition of the affected individual, so the etiological treatment is meaningless. The current conventional treatment is to prevent hypoxia, dehydration, and infection to relieve symptoms, reduce organ damage complications, promote hematopoiesis and prolong life.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of Antiplatelet Thrombolysin in Preparation of Drugs for Treating Anemia
  • Application of Antiplatelet Thrombolysin in Preparation of Drugs for Treating Anemia
  • Application of Antiplatelet Thrombolysin in Preparation of Drugs for Treating Anemia

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0030] Example 1 Antiplatelet Thrombolysin Reduces Platelet-Neutrophil Aggregation in Mouse Model of Sickle Cell Anemia Induced by TNF-α

[0031] Neutrophils (neutrophil) play a very important role in the non-specific cellular immune system of the blood. Activated neutrophils reach the lesion site through chemotaxis, and the bactericidal substances they carry will be released in large quantities locally, causing tissue damage through their respective destructive effects, and further causing organ disorders. After neutrophils invade an organ, they will Induces accumulation of neutrophils in other vital organs, resulting in multi-organ damage. At the same time, platelet selective receptors mediate the binding and adhesion of activated platelets and neutrophils, neutrophils aggregate, and accelerate tissue damage; on the other hand, platelets and neutrophils adhere to promote platelet aggregation and mediate vascular occlusion , at the same time, the cell membrane of neutrophils...

Embodiment 2

[0039] Example 2 Therapeutic effect of antiplatelet thrombolysin on sickle cell anemia mice

[0040] Chimeric control and Berkeley mice were generated by transplanting Berkeley mouse bone marrow into 6-week-old lethally irradiated WT mice. Chimerism was confirmed by PCR and electrophoretic analysis 3 months after transplantation. These chimeric Berkeley The mice are sickle cell anemic mice. The mice that have successfully established the model were taken, and severe inflammation was induced by intraperitoneal injection of 500ng TNF-α, and single-blind administration was used after 3 hours of induction. The administration groups included: IgG control (1.5 μg / g), antiPDI (BD34, 1.5 μg / g) , BSA (25ng / g), anfibatide (25ng / g), antiPDI (1.5μg / g)+anfibatide (25ng / g).

[0041] After administration, the intravital microscope was used to observe the survival time of each mouse during the study period. The recording time started from the injection of TNFα and ended when the mice died or...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to the field of medicine, and discloses the application of antiplatelet thrombolysin in the preparation of drugs for treating anemia. It is confirmed by in vivo and in vitro experiments that the anti-platelet thrombolysin of the present invention can significantly reduce platelet-neutrophil aggregation in anemic living organisms, prolong the survival time of anemic living organisms, and has good clinical application prospects.

Description

technical field [0001] The invention relates to the field of medicine, in particular to the application of an anti-platelet thrombolysin in the preparation of drugs for treating anemia. Background technique [0002] Anemia is a common clinical symptom, which refers to a state in which the total amount of red blood cells in human blood is reduced below the normal value. It can be caused by diseases of various systems. Because the determination of red blood cell volume is complicated, it is often replaced by the concentration of hemoglobin Hb in clinical practice. [0003] There are different classifications of anemia based on different clinical features. Divided into acute and chronic anemia according to the speed of anemia progress; divided into macrocytic anemia, normocytic anemia and microcytic hypochromic anemia according to the shape of red blood cells; divided into mild, moderate, severe and very severe anemia according to the concentration of hemoglobin; Proliferative...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K38/48A61P7/06
CPCA61K38/48A61P7/06A61K38/1703A61K38/4806
Inventor 楚在玹李小羿戴向荣
Owner ZHAOKE PHARMA HEFEI